Oncolix, Inc. (AEPP)

Michael T. Redman, Chairman of the Board of AEPP, called in to SmallCapVoice.com to go over their cancer drug Prolanta™,a targeted therapeutic protein for the treatment of ovarian, breast and other cancers. The Company has a US FDA-cleared IND to commence human testing of Prolanta™ in our first indication, the treatment of ovarian cancer. This clinical trial began in 2016. Preliminary data from the first dosing group (the low dose) of this trial suggest Prolanta is safe with some evidence of efficacy in a patient population that is difficult to treat. Prolanta™ is a prolactin receptor antagonist that has demonstrated significant efficacy in xenograft models through a unique mechanism of action, autophagy (see Our Science). In addition to ovarian cancer, there is strong preclinical evidence Prolanta™ will be effective in breast, prostate and other cancers.

The FDA has also approved the designation of Prolanta™ as an Orphan Drug for the treatment of ovarian cancer, which may allow reduced filing fees, federal tax credits and marketing exclusivity by the FDA.

This interview may include forward looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.